ImmuneВладониксCytomax thymus bioregulator

Vladonix

Commercial Khavinson-line 'thymus bioregulator' · ZERO product-specific peer-reviewed evidence

Vladonix is a commercial 'thymus bioregulator' sold within the Khavinson / St. Petersburg Institute of Bioregulation and Gerontology product world — and the single most important fact about it is that it has essentially no scientific literature of its own. A search of PubMed for 'Vladonix' returns zero results. Everything claimed about it is borrowed from the general body of work on thymic peptides, which is published almost entirely under a different name, Thymalin (which itself is a single-school, weakly-evidenced Russian extract). In practice Vladonix is best understood as a retail rebrand or parallel label for the same thymic-peptide concept as Thymalin, not as a separately studied or validated product. It is sold in two technological forms that matter for understanding what it even is: a 'Cytomax' natural form, which is a thymus-tissue extract — a mixture of many peptides with no single molecular formula, weight or sequence — and a 'Cytogen' synthetic form, claimed to be built from short defined peptides (plausibly the KE/Lys-Glu and EW/Glu-Trp dipeptides that the originating school identifies as the thymus line's actives). But no primary source confirms that Vladonix specifically is those dipeptides, so even that identity is an inference, not a verified fact. There is no FDA approval, no validated human dosing, and no independent replication. The honest framing here is strong skepticism: a commercial longevity/immune product whose evidence is entirely inherited from a single research school's work on a differently-named extract, and whose own chemistry — if it's the natural extract form — cannot be reduced to a single molecule at all.

The short version

Vladonix is sold as a 'thymus bioregulator' — part of a family of commercial peptide products tied to the Russian Khavinson research lineage. The most important thing to know is that it has no scientific literature under its own name: searching PubMed for 'Vladonix' returns nothing at all. So any health claim made for it is not based on studies of Vladonix; it's borrowed from research on thymic peptides published under a different name, Thymalin — which is itself a weakly-evidenced, single-school Russian extract.

It comes in two forms, and the difference matters for understanding what you're even looking at. The 'natural' (Cytomax) form is a thymus-tissue extract — a mixture of many small peptides with no single chemical formula, weight or sequence, like a broth named for its source. The 'synthetic' (Cytogen) form is claimed to be made from a couple of short, defined peptides (the same Lys-Glu and Glu-Trp dipeptides the originating school points to as the active pieces of its thymus line). But crucially, no independent source actually confirms that Vladonix is those specific peptides — that's a reasonable guess based on the product family, not a verified fact.

Putting it together: there's no FDA approval, no validated human dose, no independent confirmation, and — for the extract form — not even a single molecule to point to. The honest way to present Vladonix is with strong skepticism. It's best understood as a retail label for the same thymic-peptide idea as Thymalin, riding entirely on one research school's work, and its own specific evidence base is effectively empty.

Molecular identity

Specs

What it is: Commercial Khavinson-line thymus 'bioregulator' (Cytomax extract form and/or Cytogen synthetic form)SPIBG/Cytomax-Cytogen commercial line (CITED)
Defined single molecule?: No — natural (Cytomax) form is a thymic peptide extract/mixturePubChem PUGREST.NotFound for 'Vladonix' / 'Cytomax peptide'
Molecular formula: Not applicable (extract); UNVERIFIED for any synthetic formPubChem NotFound
Claimed synthetic actives: Short peptides of the KE (Lys-Glu) / EW (Glu-Trp) family — product-specifically UNVERIFIED for VladonixLineage inference from PMID 37686182 (Thymalin actives); NOT Vladonix-confirmed
CAS / UNII: Not applicable — not asserted (undefined product identity)No CAS or UNII; no single defined molecule for 'Vladonix'
Molecular target: No defined molecule and no classic receptor; claimed thymic/immune 'bioregulator' effect inherited from the Thymalin concept (not Vladonix-specific)Khavinson-school framework (not independently established)
Half-life: Not established (undefined product; no pharmacokinetics)Not established
Vladonix-specific PubMed literature: None — 'Vladonix' returns 0 PubMed recordsPubMed esearch (verified 2026-05-30)
Evidence base: Borrowed entirely from the general Thymalin / thymic-peptide corpus (293 Thymalin hits), single-school (Khavinson/SPIBG)PubMed counts
Regulatory status: NOT FDA-approved; Russian peptide-bioregulator / dietary-supplement (БАД) channel; Western grey-market onlyAbsence of FDA record; commercial sources (CITED)

Plain English

Mechanism

The claimed mechanism for Vladonix is the standard Khavinson 'peptide bioregulator' thesis applied to the thymus. The thymus is where T-lymphocytes mature, and the claim is that thymus-derived or thymus-mimicking peptides restore T-cell maturation, cellular immunity, and 'non-specific resistance,' especially in aging or immunosuppressed organisms. The originating school's recent work attributes to the dipeptide KE (Lys-Glu) a role in stimulating cellular immunity and non-specific resistance.

A second strand of the claim is gene-expression / epigenetic modulation: the proposal that these short peptides enter cells and nuclei and tune gene expression and protein synthesis. This is the same model invoked across the Khavinson short-peptide program.

The status must be stated bluntly: this mechanism is claimed and modelled by a single research school (SPIBG/Khavinson), and — critically — it is described for the thymus-peptide concept in general (under the name Thymalin), not for Vladonix specifically. There is no Vladonix-specific mechanistic evidence at all. Read this as a low-confidence, inherited claim about a product family, not an established mechanism for this particular label.

Sources:PMID 37686182

Why people reach for it

Potential benefits

Vladonix is sold as a 'thymus bioregulator' — here is what draws people to it, framed with the heavy skepticism a product with zero literature of its own demands.

The thymus/immune slot in a Khavinson routine — Vladonix is the retail 'thymus' label in the Khavinson product world, so people building a tissue-by-tissue bioregulator protocol reach for it as the immune piece — a marketing position, not a demonstrated effect.
A retail stand-in for the Thymalin concept — It is best understood as a parallel commercial label for the same thymic-peptide idea as Thymalin, which is why it appeals to people who want that concept in an easy consumer product — though its own evidence base is effectively empty.
An aging-focused, course-based supplement — Used the way the rest of the line is used — short periodic courses aimed at immune resilience and longevity — which draws people already invested in the bioregulator approach.
Points toward the immune levers that do work — The most defensible reason to engage with its thymic framing is that it points at immune support at all — and the proven levers there (zinc sufficiency, vitamin D, protein, sleep) vastly outweigh the product itself.

Sources:PMID 37686182 PMID 33575961

What people reach for Vladonix for, based on how it is marketed and used — NOT proven outcomes. Vladonix has zero PubMed literature under its own name and no confirmed molecular identity, so none of these are demonstrated effects or medical claims.

Implied timing

Best time to dose

Implied best time

Anytime (consistent)

Time of day isn't critical for Vladonix — pick a consistent daily time within the cycle and hold it.

Vladonix has no confirmed molecular identity and no pharmacokinetics — no half-life, no absorption data — so there is nothing to time a dose against. Day-to-day consistency is the only lever.
As a thymic/immune product, a mild evening lean is reasonable on the logic that immune consolidation and repair run overnight — but that is a soft rationale borrowed from the concept, not a Vladonix finding, and any consistent time is equally defensible.
If it is cycled alongside other Khavinson-line peptides, fixing it to the same daily slot is the simplest way to keep the course consistent.

No study establishes an ideal time of day for Vladonix — there is no product-specific literature at all, and no pharmacokinetics to reason from. This is a consistency recommendation. As a general rule peptide dosing lands in the midday-to-evening window; for Vladonix any consistent time works, with at most a mild evening lean.

Sources:PMID 37686182

How to run it

Dosing & protocol

Vladonix is an injectable research peptide — it is subcutaneously administered; the calculator on this page is built for that route. There is no validated human dose. The vendor convention (unverified marketing) is approximately 10 mg/day over a 10–30 day cycle. Every number below is that convention, labeled as such — not a clinical finding. Read this as a map of how injectable Vladonix is typically run, not a validated prescription.

ZERO validated evidence: Vladonix has no PubMed literature under its own name, no molecular identity confirmed, no human trial, and no FDA approval. Vendor dosing is unverified marketing, not peer-reviewed data. This page carries the highest skepticism in the thymic cluster — every number is vendor convention or community extrapolation, not clinical evidence.

Dose — vendor convention only, unverified

The only dosing figure in circulation comes from commercial vendor material. It is not backed by any clinical study of Vladonix.

Vendor convention:: ~10 mg/day subcutaneously for 10–30 days — this is the Khavinson-line retail marketing pattern, not a peer-reviewed protocol. No dose-ranging study of any kind exists for Vladonix.
What 'unverified' means:: There is no dose-finding trial, no pharmacokinetic study, and no human efficacy data for Vladonix under its own name. Vendor figures are marketing claims about a product with zero independent scientific literature. Treat the 10 mg/day figure as a starting reference, not a validated dose.
No Thymalin transfer:: The injectable Thymalin regimens studied by the Khavinson school (often higher-dose, clinically administered courses) are NOT transferable to Vladonix — it is a differently-named retail label, and borrowing those regimens would misrepresent the evidence.

Subcutaneous administration

Vladonix is reconstituted and injected subcutaneously — the same basic mechanics as other thymic research peptides.

Injection site:: The abdomen (staying a couple of inches clear of the navel), the love-handle area, or the outer thigh. Rotate sites between doses — using the same spot repeatedly causes local irritation and lipohypertrophy (fatty lumps under the skin).
Measuring the dose:: Drawn on a U-100 insulin syringe from the reconstituted vial. At the default mix (10 mg vial + 2 mL bacteriostatic water = 5,000 mcg/mL), the vendor 10 mg/day dose sits at 2 mL — the full vial over the day; adjust the vial/water ratio as needed for the syringe volume you want to work with. The on-page calculator handles any vial-size math.
Time of day:: No validated timing data for Vladonix — see Best time to dose above. Community convention for immune/thymic peptides is to inject once daily, morning or evening — pick a consistent time and hold it across the cycle, with at most a mild evening lean on immune-rhythm logic.
Food window:: Subcutaneous injection bypasses the gut, so there is no meaningful food-timing interaction. Inject independent of meals.

Cycle & washout

Vendor convention is a short defined course, not indefinite daily use — consistent with how the broader Khavinson bioregulator line is marketed.

Standard cycle:: 10–30 days of daily subcutaneous use, per vendor convention. The originating school's clinical work on thymic peptides (under the Thymalin name) used course lengths in this general range — but those are NOT Vladonix data.
Repeat interval:: Vendor material suggests repeating the course a few times a year (e.g. quarterly) rather than continuous dosing. This is marketing convention, not evidence.
Washout:: At minimum equal to the cycle length between repeat courses. With zero safety or pharmacokinetic data for Vladonix, the honest position is: take the full planned break and do not compress it.

Reconstitution at a glance

Mixing math for a 10 mg vial — the calculator does this live for any vial size.

Mixing:: 10 mg vial + 2 mL bacteriostatic water = 5,000 mcg per mL (= 5 mg/mL). On a 100-unit (1 mL) insulin syringe: 1,000 mcg = 20 IU · 2,500 mcg = 50 IU · 5,000 mcg = 100 IU (full syringe). For finer control, add more bacteriostatic water: 10 mg + 5 mL = 2,000 mcg/mL, so 1,000 mcg = 50 IU.
Why dilution matters:: Higher dilution spreads each dose across more syringe units, reducing the risk of measuring errors on small daily doses. Use whichever volume is most comfortable to draw and inject accurately.

Sources:PMID 37686182 Khavinson-line vendor material (CITED)

Substrate the signal needs

Nutritional cofactor precision

Vladonix's entire pitch is thymic and immune support. The practically useful move is to ensure the nutrition that immune function actually runs on is in place — independent of whether Vladonix does anything. These cofactors are reasoned from the claimed thymic/immune positioning via three questions: what amplifies the effect, what supplies the substrate, and what mitigates any cost. This is general immune nutrition applied to the product's claimed angle, not a Vladonix cofactor study. The underlying claim is itself unproven.

Reasoned from the thymic/immune positioning, not from a Vladonix-specific study (none exists). Supplement doses are standard community ranges. Zinc is the genuine anchor — its role in thymic function is textbook; everything else is supportive context.

Amplify — zinc, vitamin D, selenium

The three nutrients most directly tied to the thymic and T-cell function Vladonix purports to support.

Zinc 15–30 mg:: Zinc is the headline cofactor for anything positioned as thymic support. It is genuinely essential for thymic epithelial integrity and T-cell development — zinc deficiency measurably shrinks thymic output, a relationship that is textbook immune nutrition, not a peptide-specific finding. A thymic signal does very little in a zinc-deficient person. Take 15–30 mg zinc picolinate or bisglycinate daily with food; pair with 1–2 mg copper bisglycinate on cycles longer than 4 weeks to prevent copper depletion.
Vitamin D 2,000–5,000 IU:: Broadly involved in immune regulation — vitamin D receptor signaling modulates both innate and adaptive immune tone, including T-cell activation thresholds. Dose to a serum 25(OH)D in the sufficient range (50–80 ng/mL); the flat numbers above are starting ranges for most adults not routinely in the sun. Take with the day's fattiest meal for absorption.
Selenium 100–200 mcg:: Antioxidant defense (via glutathione peroxidase) that immune cells rely on during active immune responses. Selenoproteins are specifically expressed in lymphoid tissue. Brazil nuts (1–2 per day) or a selenomethionine supplement; do not exceed 400 mcg/day — selenium has a narrow therapeutic window.

Supply — protein and vitamin C

The raw materials immune cells are built from and the oxidative-defense cofactor they burn through fastest.

Protein ≥1.2–1.6 g/kg/day:: Antibodies, cytokines, and immune cells are built from amino acids. Immune function is measurably impaired with protein restriction — this is not a peptide-optimization nuance, it is basic nutrition physiology. Hit this range from whole food (meat, fish, eggs, legumes); peptides do not substitute for adequate substrate.
Vitamin C 500–1,000 mg:: Immune cells accumulate vitamin C to very high concentrations and burn through it rapidly during immune challenges. Divided doses (250–500 mg twice daily) maintain blood levels better than a single large bolus. Whole-food sources (citrus, bell peppers, kiwi) or ascorbic acid supplement.

Mitigate — sleep and recovery

The 'supplement' that governs immune function more than any capsule.

Sleep 7–9 hours:: Immune function is well-documented to degrade with sleep deprivation — natural killer cell activity, T-cell response, and cytokine signaling all decline acutely after poor sleep. No thymic bioregulator compensates for chronic sleep debt. If the goal is immune resilience, consistent sleep is non-negotiable, not optional.
Stress management:: Chronic cortisol elevation suppresses T-cell counts and shrinks the thymus (involution). The honest frame: if cortisol is chronically elevated, a thymic peptide is trying to restore what the stress keeps destroying. Addressing the upstream driver is higher-leverage than any supplement.

Combinations + timing

Stacking notes + timing windows

Vladonix is placed in the thymic/immune category. Two stacking approaches exist: grouping with other Khavinson-line bioregulators (the community convention), or pairing with Thymosin Alpha-1 — the better-characterized thymic peptide with actual peer-reviewed evidence. The honest caveat on both is stated first: with zero independent evidence for Vladonix, any stack is speculation layered on speculation.

Double speculation: Vladonix itself has no clinical evidence, so stacking it adds another unproven variable on top of an already-unproven base. Both options below are community convention and mechanistic reasoning, not studied combinations. The Thymosin Alpha-1 pairing is meaningfully more defensible — it at least has a characterized molecule and peer-reviewed human data on one side of the pair.

Vladonix + Khavinson bioregulator family

The community convention — cycling Vladonix alongside other Khavinson-school thymic/immune labels (Thymalin, Thymogen, Thymulin).

Why it works:: These products share the same single-school mechanistic thesis (thymic peptide bioregulation) and the same institutional origin. The Khavinson community groups them as 'immune bioregulators' and commonly cycles them together or in sequence, reasoning that each covers slightly different thymic-peptide fractions. This is mechanistic family resemblance, not studied synergy.
The protocol:: Vendor convention: Vladonix ~10 mg/day in its defined course; other Khavinson-line bioregulators run on their own respective vendor cycles. Stacking them simultaneously compounds the unknowns — sequencing (one course, then another) is a somewhat more conservative approach when working with undefined extracts.
Outcome:: Reached for on broad immune-resilience and longevity goals within the Khavinson protocol framework. Understand the compounding unpredictability: combining several products of undefined, extract-based composition means the combined effect is as unknown as each individual one.

Vladonix + Thymosin Alpha-1

The more defensible immune pairing — adds a well-characterized thymic peptide with actual peer-reviewed human data to the combination.

Why it works:: Thymosin Alpha-1 (Tα1) is the characterized, sequenced thymic peptide with published human clinical data (FDA-approved in some indications outside the US, studied in cancer, chronic viral infection, and immune-deficiency contexts). Pairing it with Vladonix gives one side of the pair that is a real, defined molecule with independent literature. The claimed thymic-maturation mechanism is similar between them — Tα1 is broadly considered the better-evidenced version of what Vladonix claims to do.
The protocol:: Thymosin Alpha-1 typical research convention: 1.5 mg subcutaneously twice weekly (1–3 mg/week range). Vladonix at vendor convention (~10 mg/day SubQ) run as its own separate 10–30 day course. Running them concurrently vs sequentially is not studied; sequential is the more conservative approach when one compound is an undefined extract.
Outcome:: Reached for when the goal is thymic/immune support and one wants at least one characterized, evidenced compound in the pairing. Note the honesty axis on the Thymosin Alpha-1 page — its most rigorous recent controlled trial was null, so even the better-characterized partner is not without skepticism. The honest framing: this is the best available pairing for Vladonix's claimed niche, not a proven synergistic combination.

Reconstitution math

Reconstitution calculator

Calculated for a 1 mL U-100 insulin syringe (100 units/mL).

Peptide per vial

BAC water added

Desired dose

Units per dose

Draw to this mark on a U-100 syringe

Volume per dose: 0.2 mL
Doses per vial: 10
Concentration: 5 mg/mL

One vial lasts

Daily: 10 days
Every other day: 20 days
5×/week: 14 days

Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.

From the studies

Side effects from research

There is no Vladonix-specific safety literature, so no verified side-effect profile can be reported. Khavinson-line bioregulators are generally marketed as well tolerated, but that is vendor framing, not independent pharmacovigilance.

The honest position is that the safety of Vladonix specifically is simply uncharacterized. If the product is an animal-thymus-derived extract, it carries the general theoretical considerations of biological extracts (reactions to foreign protein material, batch-to-batch variability) on top of the complete absence of an independent safety database.

Gray-market sourcing adds purity and identity risk independent of any active ingredient. The fair summary: no documented serious harm, but also no real safety evidence — the reassurance you'd want simply doesn't exist for this label.

As reported in literature

Research dosing ranges

There is no Vladonix-specific dosing or efficacy literature — 'Vladonix' returns zero PubMed records. The rows below are from the general Khavinson THYMALIN / thymic-peptide corpus and are shown ONLY to characterize the inherited evidence base; none of them studied Vladonix. Do not read them as Vladonix data. No validated human dose exists for this product.

Dose	Route	Model	Outcome	Sources:
Not Vladonix-specific	In vitro / modelling	Thymalin actives study — KE/EW dipeptides & gene expression (Linkova 2023)	Defines Thymalin as a thymus EXTRACT and names KE/EW as its actives; the basis for inferring (UNVERIFIED) Vladonix's synthetic-form identity — but studied Thymalin, not Vladonix	PMID 37686182
Not Vladonix-specific	Clinical context	Khavinson-school COVID-19 complex-therapy report (2021)	Hematopoietic stem-cell differentiation activator in complex therapy; Khavinson-school clinical-context claim — about the thymic-peptide concept generally, not Vladonix	PMID 33575961
Not Vladonix-specific	Animal (aging)	Pineal/thymus aging study, Adv Gerontol 2004 (Russian school)	Older Russian-school thymus/aging work; representative of the single-school corpus Vladonix's claims borrow from, not a Vladonix study	PMID 15490729
~10 mg/day ×10–30 d	Oral or SubQ (vendor pattern)	Commercial vendor usage pattern (UNVERIFIED — marketing, not trial)	Typical retail 'bioregulator' cycle; no peer-reviewed efficacy data, not clinically established, no Vladonix trial behind it	Khavinson-line vendor material (CITED)

Quick answers

Frequently asked

Is there any actual research on Vladonix?

Essentially none under its own name — a PubMed search for 'Vladonix' returns zero records. Every claim made for it is borrowed from the general thymic-peptide literature published under the name Thymalin, which is itself single-school and weakly evidenced. There is no Vladonix-specific study to point to.

What is Vladonix made of?

It depends on the form. The 'natural' (Cytomax) form is a thymus-tissue extract — a mixture of peptides with no single formula or sequence. The 'synthetic' (Cytogen) form is claimed to be short defined peptides (plausibly the KE/Lys-Glu and EW/Glu-Trp dipeptides), but no primary source confirms that Vladonix specifically is those peptides. Either way, don't expect a single defined molecular identity.

Is it the same as Thymalin?

It's best understood as a retail rebrand or parallel label for the same thymic-peptide concept as Thymalin — but they are not verified to be identical, and Thymalin's (already weak) evidence should not be transferred onto Vladonix as if it were. Thymalin is the injectable extract that the literature actually studied; Vladonix is a differently-named retail product.

Is there a validated dose?

No. No validated human dosing exists for Vladonix. Vendor material commonly cites something like ~10 mg/day in 10–30 day subcutaneous cycles, but that's marketing, not peer-reviewed evidence, and there's no Vladonix trial behind it.

Should I be skeptical of Vladonix?

Yes — strongly. It has no scientific literature of its own, its evidence is entirely inherited from one research school's work on a differently-named extract, its chemistry (in the natural form) can't be reduced to a single molecule, and it isn't FDA-approved. That combination warrants treating its claims with heavy skepticism.

How does Vladonix compare to Thymosin Alpha-1?

Thymosin Alpha-1 is considerably more defensible: it is a single characterized peptide with a confirmed sequence and molecular identity, and it has peer-reviewed human clinical data (including controlled trials). Vladonix has none of those things. If the goal is thymic/immune support, Thymosin Alpha-1 is on meaningfully firmer scientific ground — though even that page notes that its most rigorous recent controlled trial was null.

Primary sources

References

PMID 37686182Linkova et al., Int J Mol Sci 2023 — KE/EW dipeptides as actives of the Thymalin thymus EXTRACT (studied Thymalin, not Vladonix)
PMID 33575961Khavinson-school report, Stem Cell Rev Rep 2021 — hematopoietic stem-cell differentiation activator in COVID-19 complex therapy (thymic-peptide concept, not Vladonix)
PMID 15490729Adv Gerontol 2004 — pineal-gland peptide factors and thymus/bone-marrow rhythms in aging animals (Russian school)
Khavinson-line vendor material (CITED)Commercial Cytomax/Cytogen 'Vladonix' product material — retail dosing pattern (secondary, marketing only, UNVERIFIED)

Research use only · Not medical advice · Updated 2026-06-01